TheBCR-ABL fusion gene is the oncogenic cause of CML pathogenesis; therefore, theoretically, knockout or disruption ofBCR-ABL would ablate the production of the BCR-ABL fusion protein, which would likely cure CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.